Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx Promotes COO to CEO, Appoints CFO

NEW YORK, Feb 5 - Zyomyx, a Hayward, Calif.-based protein chip company, said Monday that Lawrence Cohen, the company’s chief operating officer, had been promoted to CEO.

The company also named Garrett Roper chief financial officer.

Cohen will replace Yasunori Kaneko, who has been CEO since 1998. Kaneko will stay on as chairman of Zyomyx’s board.

A spokeswoman for Zyomyx said that Kaneko had been working as a part-time CEO and that Cohen’s promotion to CEO reflected the his effectiveness as COO.

Zyomyx, which has an agreement with Cambridge Antibody Technology to jointly develop high-density protein chips, is scheduled to begin beta testing its protein chips sometime in the first half of this year. Other companies currently developing protein arrays include Motorola, Proteome Systems, Protein Sciences Corporation, HTS Biosystems, Oxford Glycosciences, Phylos, and Packard Biosciences.

The privately-held company recently raised $32.6 million in private financing.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.